EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety and effectiveness of lenalidomide in Japanese patients with relapsed/refractory ATLL: post-marketing surveillance

Tohru Miyazaki, Shuji Uno, Hiroaki Fujimori, Yoko Motegi

International Journal of Hematology · 2025

DOI: 10.1007/s12185-024-03864-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Hematology, 2025. Verfasst von Tohru Miyazaki und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hematology, Japan Medical, Bristol Myers Squibb, Otemachi One Tower, 1-2-1 Otemachi, Chiyoda-Ku, Tokyo, 100-0004, Japan. Tohru.Miyazaki@bms.com. Hauptthemen laut MEDLINE: Lenalidomide, Product Surveillance, Postmarketing, Leukemia-Lymphoma, Adult T-Cell. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lenalidomide is an oral immunomodulatory agent approved for the treatment of relapsed/refractory adult T-cell leukemia/lymphoma (ATLL) in Japan. Post-marketing surveillance (PMS) was conducted to confirm its safety and effectiveness. From April 2017 until April 2020, safety data were obtained for 77 patients and effectiveness data for 65 patients (31.2% of patients had progressive disease as the best response to their most recent prior regimen). Forty-nine patients (63.6%) in the safety analysis set experienced an adverse drug reaction (ADR). Grade ≥ 3 ADRs occurred in 42.9%. The most common Grade ≥ 3 ADRs were neutrophil count decreased/neutropenia and platelet count decreased/thrombocytopenia (11.7% each). Serious ADRs occurred in 26 patients. Five patients had previously received allogeneic hematopoietic stem cell transplantation. Among these, one experienced acute graft versus host disease (GvHD) during lenalidomide administration and two responded to lenalidomide. Effectiveness analysis showed that an objective response was achieved in 29.2% of patients. No statistically significant differences were observed in the objective response rates of patients aged < 70 versus those aged ≥ 70 years (33.3% vs 28.0%, respectively; p = 0.6904). No new safety signals were observed in this PMS, and lenalidomide demonstrated a favorable benefit-risk balance in Japanese patients with ATLL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LenalidomideProduct Surveillance, PostmarketingLeukemia-Lymphoma, Adult T-CellHumansAgedMaleFemaleMiddle AgedJapanAdultTreatment OutcomeRecurrenceAged, 80 and overHematopoietic Stem Cell TransplantationEast Asian People

Stichwörter der Autor:innen

Adult T-cell leukemia/lymphomaJapanese patientsLenalidomidePost-marketing surveillanceRelapsed/refractory

Substanzen

Lenalidomide

Autor:innen und Institutionen

  • Hematology, Japan Medical, Bristol Myers Squibb, Otemachi One Tower, 1-2-1 Otemachi, Chiyoda-Ku, Tokyo, 100-0004, Japan. Tohru.Miyazaki@bms.com.
  • Hematology, Japan Medical, Bristol Myers Squibb, Otemachi One Tower, 1-2-1 Otemachi, Chiyoda-Ku, Tokyo, 100-0004, Japan.
  • PMS Operations, Worldwide Patient Safety Japan, Bristol Myers Squibb, Tokyo, Japan.

Förderung

  • Bristol Myers Squibb

Zitieren

APA

Miyazaki, T., Uno, S., Fujimori, H., & Motegi, Y. (2025). Safety and effectiveness of lenalidomide in Japanese patients with relapsed/refractory ATLL: post-marketing surveillance. International Journal of Hematology. https://doi.org/10.1007/s12185-024-03864-3

Vancouver

Miyazaki T, Uno S, Fujimori H, Motegi Y. Safety and effectiveness of lenalidomide in Japanese patients with relapsed/refractory ATLL: post-marketing surveillance. International Journal of Hematology. 2025. doi:10.1007/s12185-024-03864-3

BibTeX
@article{Miyazaki2025,
  author = {Miyazaki, Tohru and Uno, Shuji and Fujimori, Hiroaki and Motegi, Yoko},
  title = {Safety and effectiveness of lenalidomide in Japanese patients with relapsed/refractory ATLL: post-marketing surveillance},
  journal = {International Journal of Hematology},
  year = {2025},
  doi = {10.1007/s12185-024-03864-3}
}
Kostenlos starten →